Background:
Immune checkpoint inhibitors (ICIs) have shown clinical benefit in many advanced
tumors, however, pseudo-progression is a noted phenomenon of ICIs characterized by radiologic enlargement of the
tumor burden, followed by regression. How to differentiate pseudo-progression from progression remains a critical clinical issue. Recent studies have demonstrated the association between immune-related adverse events (irAEs) and efficacy of ICIs. Here we demonstrated an
ovarian cancer patient treated with
nivolumab in whom the early-onset irAE was identified to differentiate pseudo-progression from progression. Case presentation: Here we present the case of a 47-years-old woman with histopathologically confirmed diagnosis of metastatic ovarian
cystadenocarcinoma. Immunohistochemical examination showed 10% of
tumor cells to express the programmed cell death receptor
ligand 1 (PD-L1) and a 381-gene panel sequencing in a College of American Pathologists (CAP) certificated lab revealed a moderate mutational
tumor burden with 5.7 Mutants/Mb. The patient received
nivolumab 100 mg every 2 weeks as a fourth line treatment. Within the first 2 months, the
tumor volume increased by 23.6%. However, the patient experienced an elevation of
Alanine aminotransferase (ALT) and
Aspartate aminotransmerase (AST), which was diagnosed as the immune-related
hepatitis. Thus, the treatment continued and afterwards, the patient reached a partial response (PR) to
nivolumab and the progression-free survival was 9 months. Conclusion: To our knowledge, this is the first case describing early-onset immune-related adverse events to identify pseudo-progression in a patient with
ovarian cancer treated with
nivolumab, and PD-L1 expression level may be a predictive
biomarker in the
immunotherapy of
ovarian cancer.